Back to News
Apr 13, 2026 8:00 AM

IDEAYA Eye Cancer Trial Data Beats Standard Therapy, Stock Soars

IDEAYA Biosciences Inc. (NASDAQ:IDYA) shares are up during Monday’s premarket session following the announcement of positive topline results from the Phase 2/3 trial for darovasertib in combination with crizotinib.

The news highlights the potential for a new treatment option for patients with metastatic uveal melanoma, a type of eye cancer.

Trial Meets Primary Endpoint

IDEAYA is a precision medicine oncology company focused on the discovery, development, and commercialization of cancer therapies.

The study showed a statistically significant improvement in median progression-free survival (PFS) for the darovasertib combination compared to the investigator’s choice of therapy (ICT).

Trial met the primary endpoint, showing statistically significant improvement in median PFS, with 6.9 months for the darovasertib combination versus 3.1 months for ICT.

Patients treated with the darovasertib combination reduced their risk of disease progression by 58%.

Secondary Endpoints Show Higher Response Rates

The secondary ...